A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

NCT06637423 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Muscle Invasive Bladder Cancer

Interventions

DRUG: Sacituzumab tirumotecan
DRUG: Rescue medication
DRUG: Supportive care measures

Sponsor

Merck Sharp & Dohme LLC